Hernández-López GD, Jiménez-López R, López-Reséndiz A, Estrada-Carreón M

Language: Spanish
References: 12
Page: 163-167
PDF size: 127.65 Kb.

ABSTRACT

Introduction. Dexmedetomidine is an α₂-receptor agonist, has analgesic, sedation, anxiolysis and sympatholysis effect. However, like other drugs, has been associated with the development of undesirable side effects wich must be taken into account when is administrate. Material and methods. We included 60 patients admitted to the Post-Surgical Special Care Unit (PSCU) that were undergoing orthopedic surgery and mechanical ventilation (MV). Thirty patients received dexmedetomidine continuous infusion and 30 received buprenorphine every 6 h. The average length of stay was 36 h. The average dose of dexmedetomidine was 3 mcg/kg/h. Results. No significant changes were observed in relation to heart rate, body temperature and serum glucose levels. Although deleterious effects have been reported associated with the use of dexmedetomidine, especially cardiovascular level, however in most cases, the studies have been performed in critically ill patients, perhaps this is the reason why we did not found adverse effects our study group because they were non-critical patients. The average time of weaning of MV was 3 h in the group treated with dexmedetomidine and 8 h in the buprenorphine group. Conclusion. The results of this study demonstrate that continuous infusions of dexmedetomidine contribute to maintaining a stable analgesic level for more than 24 h in patients with orthopedic surgery and facilitates the weaning of MV.

REFERENCES

1. Ruokonen E, Parviainen I, Jakob MS, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Int Care Med 2009; 35: 282-90.

2. Oto J, Yamamoto K, Koike S, et al. Sleep quality of mechanically ventilated patients sedated with dexdemetomidine. Int Care Med 2012; 38: 1982-9.

3. Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients sedative and cardiovascular effects. Int Care Med 2004; 30: 2188-96.

4. Tan AJ, Ho MK. Use of dexmedetomidine as a sedative an analgesic agent in critically ill adult patients: a meta-analysis. Int Care Med 2010; 36: 926-39.

5. Joffe MA, Hallman M, Gélinas G, et al. Evaluation and treatment of pain in critically ill adults. Semin Respir Crit Care Med 2013; 34: 189-200.

6. Venn MR, Hell J, Grounds M. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 2000; 4: 302-8.

7. Pandharipande PP, Sanders DR, Girard DT, et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care 2010; 14: R38.

8. Duan M, Lee J, Britner AE. Dexmedetomidine for sedation in the parturient with respiratory failure requiring noninvasive ventilation. Respir Care 2012; 57(11): 1967-9.

9. Reardon PD, Anger EK, Adams DCh, et al. Role of dexmedetomidine in adults in the intensive care unit: an update. Am Health Syst Pharm 2013; 70(1): 767-77.

10. Shehabi Y, Botha AJ, Ernest D, et al. Clinical application, the use of dexmedetomidine in intensive care sedation. Crit Care and Shock 2010; 13: 40-50.

11. Riker RR, Shehabi Y, Bokesh MP, et al. Dexmedetomidine vs. midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301(5): 489-99.

12. Devlin WJ, Fraser LG, Ely Wesley E, et al. Pharmacological management of sedation and delirium in mechanically ventilated ICU patients: remaining evidence gaps and controversies. Semin Respir Crit Care Med 2013; 34: 201-15.